New emergency contraceptive available
16th October 2009
HRA Pharma, a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne® (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.
ellaOne® is the first representative of a new therapeutic class, selective progesterone receptor modulators, and is the first molecule to have been specifically designed and developed for use as an oral emergency contraceptive. Clinical trials performed on more than 4000 women have shown that a single dose of ellaOne significantly reduces the number of pregnancies versus the number of expected pregnancies in absence of emergency contraception. ellaOne is different from currently used levonorgestrel-based emergency contraceptives, in that it maintains efficacy for 5 days after unprotected intercourse while its safety and tolerability profile has been demonstrated to be comparable to that of levonorgestrel.
The full press release can be downloaded here.